Weight plays a role in the effects of CBD oil, and bottle size should be selected based on how much you weigh. Let’s say you weigh less than 130 pounds and desire light CBD oil effects; this means that 11 mg or less will probably suffice per dose, giving roughly 40 doses from a 450-mg concentration. If you weigh more than 230 pounds and desire strong effects, then this same concentration will supply roughly 10 doses. 

Do not use cannabis if you are pregnant or could become pregnant. There is some evidence that women who smoke cannabis during the time of conception or while pregnant may increase the risk of their child being born with birth defects. Pregnant women who continue to smoke cannabis are probably at greater risk of giving birth to low birthweight babies.
"The term ‘“marihuana” means all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin. Such term does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination.140
While CBD still faces legal hurdles to go mainstream, beverage giants, food companies and others have begun to take serious interest in the roughly $2 billion U.S. market. Tilray Inc. TLRY, +0.68%  announced a partnership with Anheuser-Busch InBev SA BUD, -1.34%  this week to research marijuana-based beverages, and Constellation Brands Inc. STZ, -0.03%   has invested heavily in pot producer Canopy Growth Corp. Other large companies, like Molson Coors Brewing Co. TAP, -0.17%  , have invested in research, and Coca-Cola Co. KO, -0.26%  and others have at least considered making a play for the space.
That’s our two cents worth. We are still reserching products with claims of effective pain relief and possibly something will work. As of right now if dot/gov can not point the now abandoned pain management patient to an effective pain management product, not willing to listen to our physicians or VERY negatively affected patients with a maximum, unilateral dosage of opioid medication new “policy”, then where do we turn for real, effective, pain management?
There has been little high-quality research into the use of cannabidiol for epilepsy, and what there is is limited to refractory epilepsy in children.[16] While the results of using medical-grade cannabidiol in combination with conventional medication shows some promise, they did not lead to seizures being eliminated, and were associated with some minor adverse effects.[16]
Based on reviews, smoking or vaporizing CBD vape oil seems to have less effects when compared to other methods of administering CBD, such as tinctures, capsules and sprays. On the flip side, others argue that smoking or vaporizing has less drawbacks than taking CBD orally, since ingesting CBD orally could result in inconsistent absorption and a delayed effect.
"No official estimates are available of the value of U.S. sales of hemp-based products. The Hemp Industries Association (HIA) reports total U.S. retail sales of hemp products of nearly $700 million in 2016,12 which includes food and body products, dietary supplements, clothing, auto parts, building materials, and other consumer products (Figure 2). HIA claims that U.S. hemp retail sales have increased by about 10% to more than 20% annually since 2011. Much of this growth is attributable to sales of hemp-based body products, supplements, and foods. Combined, these categories accounted for more than two-thirds of the value of U.S. retail sales in 2016.
Not surprisingly, the data we have are messy. Berenson, in his role as devil’s advocate, emphasizes the research that sees cannabis as opening the door to opioid use. For example, two studies of identical twins—in the Netherlands and in Australia—show that, in cases where one twin used cannabis before the age of seventeen and the other didn’t, the cannabis user was several times more likely to develop an addiction to opioids. Berenson also enlists a statistician at N.Y.U. to help him sort through state-level overdose data, and what he finds is not encouraging: “States where more people used cannabis tended to have more overdoses.”

Israel, another example, has led the way with ground-breaking research into cannabis cultivation. The country recently recognized medical marijuana as an official part of the nation’s branch of agriculture. Israel is already one of the world’s leading exporters of medical-grade cannabis. Recognizing marijuana cultivation as an official branch of the country’s agriculture will open up even more funds to support Israeli cannabis farmers.
The great positive impact of public health programs is widely acknowledged. Due in part to the policies and actions developed through public health, the 20th century registered a decrease in the mortality rates for infants and children and a continual increase in life expectancy in most parts of the world. For example, it is estimated that life expectancy has increased for Americans by thirty years since 1900,[55] and worldwide by six years since 1990.[56]
In 2017, China imported more than $24 billion in agriculture products from the U.S. The world’s top wheat consumer, China and purchased 1.6 million tons of U.S. wheat worth $391 million. At the same time, China bought $14 billion in soybeans for personal and animal consumption from the U.S. last year--more than any other agricultural commodity, and the country's corn imports from the U.S. were worth $160 million.
The major symptom of many short and long-term illnesses is pain, both chronic and acute. Disorders such as Multiple Sclerosis, Diabetic Neuropathy and others, whether derived from the primary or central nervous system, leave patients with unrelenting pain not easily controlled by common pain medications. Although few randomized clinical trials over sufficiently extended periods of time measuring the effects of cannabidiol oil intake on pain management exist, preliminary studies suggest the use of CBD’s in chronic pain management to be useful allowing an increase in quality of life and the ability to rest without pain.  There is some research out there that suggests this might be a good solution for those that are sensitive to other medications as well.  We have attached some Medical publications, News Articles and some videos that touch on this subject.
Hi I've had rsd over 25 years now and in stage 3 I take cbd I'mor nong 6 weeks now and it's helped tons w my depression,sleep,constipation as well as energy. I take 2 drops under tounge every morning and Rick spson oil 3 xs day.It's bern beyond life changing for me look into the rs oil w the cbd. It works.. I still take 1 opiad a day have taken 2 a day only 3 times in almost 2 months when I was in bad flare ..
Prior to the Hemp Farming Act of 2018, 41 states had passed industrial hemp-related legislation. 39 of those states legalized statewide hemp cultivation programs that defined hemp specifically to differentiate it from marijuana, establish licensing requirements, and regulate production. The Hemp Farming Act now requires state departments of agriculture to consult with their governors and chief law enforcement officers on a hemp regulatory program, which will then be submitted to the United States Secretary of Agriculture for approval. According to Section 297B of the bill, state hemp regulatory programs must include a system to maintain information on all land on which hemp is cultivated, procedures for testing THC levels in hemp, and procedures for disposing of products that violate THC content restrictions.
Born in the foothills of the Rocky Mountains, we’ve been growing some of the safest and most thoroughly tested medical cannabis on the market since 2016. Our state-of-the-art facility in Cremona, Alberta, was specifically designed to keep our plants happy, and alongside a meticulous process of harvesting and curing we ensure only the best product arrives at your door.
In 2015, researchers conducted a comprehensive review to get at the heart of CBD and its intervention of addictive behaviors. These researchers gathered 14 studies, nine (9) of which involved animals, while the remaining five (5) involved humans, to find that CBD may indeed have therapeutic properties on opioid, cocaine, and psychostimulant addiction. Further, studies heavily suggest that CBD may also be beneficial in the treatment of marijuana and tobacco addiction. One reason that CBD may be effective as treatment for addictive disorders is its ability to ease the anxiety that leads people to crave drugs like heroin.
Figuring out how much CBD oil to take can feel like trying to navigate through a complicated maze. The sheer volume of CBD brands on the market can create confusion for consumers, and when you take a closer look, it’s not difficult to understand why. Not only do vendors use different source materials (CBD-rich cannabis vs. industrial hemp, different strains, etc.), but they also implement different extraction techniques .
"The survey covers the harvest of 2013, related to a total cultivation area of 15,700 ha. The first figure shows the development of the cultivation area since 1993. Between 1993 and 1996 the cultivation of industrial hemp was legalised in most of the member states, others followed later. In 2011 the cultivation area decreased to its lowest value since 1994 (ca. 8,000 ha), but increased in 2012, 2013 and 2014, to finally reach 25,000 ha in 2015. In 2016 a further increase is expected. The main cultivation member states are France and The Netherlands. In recent years, many new European countries started or expanded their hemp cultivation, mainly for the production of hemp seeds.
Given the uncertainties and handicaps associated with hemp, it is fortunate that there are compensating factors. As noted, as a crop hemp offers some real environmental advantages, particularly with regard to the limited needs for herbicides and pesticides. Hemp is therefore pre-adapted to organic agriculture, and accordingly to the growing market for products associated with environmentally-friendly, sustainable production. Hemp products are an advertiser’s dream, lending themselves to hyperbole (“healthiest salad oil in the world,” “toughest jeans on the market”). While the narcotics image of C. sativa is often disadvantageous, advertisers who choose to play up this association do so knowing that it will attract a segment of the consuming population. In general, the novelty of hemp means that many consumers are willing to pay a premium price. It might also be said that those who have entered the hemp industry have tended to be very highly motivated, resourceful, and industrious, qualities that have been needed in the face of rather formidable obstacles to progress.
In the 1950s, the Narcotics Control Act and the Boggs Act stiffened penalties for marijuana possession, with first-time offenses requiring two to 10 year sentences and a minimum $20,000 fine, according to PBS.org. Penalties were relaxed in the 1970s, but President Ronald Reagan increased federal penalties for marijuana possession in the 1980s. On the federal level, marijuana is now regulated under the Controlled Substances Act as a schedule 1 drug, meaning the government considers it to have a high potential for abuse with no legitimate medical or therapeutic uses.
Did you know that pain is the number one reported condition for medical marijuana cards in the U.S.? In Colorado alone, 92% of patients, over 86,000 people, use cannabis to treat their chronic pain. Research on CBD and pain management has shown great promise and people are increasingly turning to cannabinoid therapy as the harms of opioids garner more attention and scrutiny.

In some areas where cannabis use had been historically tolerated, new restrictions were instituted, such as the closing of cannabis coffee shops near the borders of the Netherlands,[222] and closing of coffee shops near secondary schools in the Netherlands.[223] In Copenhagen, Denmark in 2014, mayor Frank Jensen discussed possibilities for the city to legalize cannabis production and commerce.[224]
"Hemp was widely grown in the United States from the colonial period into the mid-1800s. Fine and coarse fabrics, twine, and paper from hemp were in common use. By the 1890s, labor-saving machinery for harvesting cotton made the latter more competitive as a source of fabric for clothing, and the demand for coarse natural fibers was met increasingly by imports. Industrial hemp was handled in the same way as any other farm commodity in that USDA compiled statistics and published crop reports33 and provided assistance to farmers promoting production and distribution.34 In the early 1900s, hemp continued to be grown, and USDA researchers continued to publish information related to hemp production and also reported on hemp’s potential for use in textiles and in paper manufacturing.35 Several hemp advocacy groups, including HIA and Vote Hemp, Inc., have compiled other historical information and have copies of original source documents.36
So-called “pure hybrids,” while oxymoronic in name, indicate marijuana strains that are believed to offer a perfect blend or balance of sativa’s energizing and indica’s sedating effects. Other hybrid strains of cannabis tend to place the emphasis on one end of the spectrum or the other. These are called “sativa-dominant” or “indica-dominant,” accordingly.
Right now, due to arcane laws that are about to change around the world, and strange licensing procedures, cannabis is a supply issue, but that will all change over time.  Cannabis is a plant that can grow in 12 weeks, 16 weeks for some Indica strains.  There will never be a shortage or issue with getting cannabis when it is a plant that can be produced anywhere in the world, in large batches, every 12 weeks.
From 1982 to 2002 the EU provided the equivalent of about 50 million dollars to develop new flax and hemp harvesting and fiber processing technologies (Karus et al. 2000). Because of the similarities of flax and hemp, the technologies developed for one usually are adaptable to the other. In addition, various European nations and private firms contributed to the development of hemp technologies. Accordingly, Europe is far more advanced in hemp development with respect to all fiber-based applications than other parts of the world. The EU currently dedicates about 30,000 ha to hemp production. France is the leading country in hemp cultivation in the EU, and 95% of the non-seed production is used for “specialty pulp” as described below. Harvesting and processing machinery for fiber hemp is highly advanced in Europe, and some has been imported into Canada. However, there is insufficient fiber processing capacity to handle hemp produced in Canada.
The high lipid-solubility of cannabinoids results in their persisting in the body for long periods of time.[140] Even after a single administration of THC, detectable levels of THC can be found in the body for weeks or longer (depending on the amount administered and the sensitivity of the assessment method).[140] A number of investigators have suggested that this is an important factor in marijuana's effects, perhaps because cannabinoids may accumulate in the body, particularly in the lipid membranes of neurons.[141]
These policies vary widely. Marijuana and CBD are currently fully legal for both medicinal and recreational purposes in Alaska, California, Colorado, Maine, Massachusetts, Michigan, Nevada, Oregon, Vermont, Washington, and Washington D.C. In 23 states, it's legal in some form, such as for medicinal purposes. Another 14 states permit just CBD oil. But both are illegal in Idaho, Nebraska, and South Dakota. For more information, the organization Americans for Safe Access has a helpful guide to the specific laws in each state.
Berenson looks, too, at the early results from the state of Washington, which, in 2014, became the first U.S. jurisdiction to legalize recreational marijuana. Between 2013 and 2017, the state’s aggravated-assault rate rose seventeen per cent, which was nearly twice the increase seen nationwide, and the murder rate rose forty-four per cent, which was more than twice the increase nationwide. We don’t know that an increase in cannabis use was responsible for that surge in violence. Berenson, though, finds it strange that, at a time when Washington may have exposed its population to higher levels of what is widely assumed to be a calming substance, its citizens began turning on one another with increased aggression.
Sativex® (GW Pharmaceuticals) is an oromucosal whole cannabis-based spray combining a CB1 partial agonist (THC) with a cannabinoid system modulator (CBD), minor cannabinoids and terpenoids plus ethanol and propylene glycol excipients and peppermint flavoring (McPartland and Russo 2001; Russo and Guy 2006). It was approved by Health Canada in June 2005 for prescription for central neuropathic pain in multiple sclerosis, and in August 2007, it was additionally approved for treatment of cancer pain unresponsive to optimized opioid therapy. Sativex is a highly standardized pharmaceutical product derived from two Cannabis sativa chemovars following Good Agricultural Practice (GAP) (de Meijer 2004), yielding Tetranabinex® (predominantly-THC extract) and Nabidiolex® (predominantly-CBD extract) in a 1:1 ratio. Each 100 μL pump-action oromucosal Sativex spray actuation provides 2.7 mg of THC and 2.5 mg of CBD. Pharmacokinetic data are available, and indicate plasma half lives of 85 minutes for THC, 130 minutes for 11-hydroxy-THC and 100 minutes for CBD (Guy and Robson 2003). Sativex effects commence in 15–40 minutes, an interval that permits symptomatic dose titration. A very favorable adverse event profile has been observed in over 2500 patient years of exposure in over 2000 experimental subjects. Patients most often ascertain an individual stable dosage within 7–10 days that provides therapeutic relief without unwanted psychotropic effects (often in the range of 8–10 sprays per day). In all RCTs, Sativex was adjunctively added to optimal drug regimens in subjects with intractable symptoms, those often termed “untreatable.” Sativex is also available by named patient prescription in the UK and the Catalonia region of Spain. An Investigational New Drug (IND) application to study Sativex in advanced clinical trials in the USA was approved by the FDA in January 2006 in patients with intractable cancer pain.
High-CBD strains tend to deliver very clear-headed, functional effects without the euphoric high associated with high-THC strains. They’re typically preferred by consumers who are extremely sensitive to the side effects of THC (e.g., anxiety, paranoia, dizziness). A high-CBD strain would also be a great choice for someone needing to medicate throughout the day to control pain, inflammation, anxiety, or other chronic conditions.
“Specialty pulp” is the most important component of the hemp industry of the EU, and is expected to remain its core market for the foreseeable future. The most important specialty pulp products made from hemp are cigarette paper (Fig. 16), bank notes, technical filters, and hygiene products. Other uses include art papers and tea bags. Several of these applications take advantage of hemp’s high tear and wet strength. This is considered to be a highly stable, high-priced niche market in Europe, where hemp has an 87% market share of the “specialty pulp” sector (Karus et al. 2000). In Europe, decortication/refining machines are available that can produce 10 t/hour of hemp fiber suitable for such pulp use. North American capacity for hemp pulp production and value-added processing is much more limited than that of Europe, and this industry is negligible in North America.
Dehulled (i.e. hulled) hemp seed is a very recent phenomenon, first produced in quantity in Europe. Hemp seeds have been used as food since ancient times, but generally the whole seed, including the hull, was eaten. Hemp seed was a grain used in ancient China, although there has been only minor direct use of hemp seed as food by humans. In the past, hemp seed has generally been a food of the lower classes, or a famine food. Peanut-butter type preparations have been produced from hemp seed in Europe for centuries, but were rather gritty since technology for removing the hulls was rudimentary. Modern seed dehulling using mechanical separation produces a smooth, white, gritless hemp seed meal that needs no additional treatment before it is consumed. It is important to understand, therefore, that the quality of modern hemp seed for human consumption far exceeds anything produced historically. This seed meal should be distinguished from the protein-rich, oil-poor seed cake remaining after oil has been expressed, that is used for livestock feed. The seed cake is also referred to as “seed meal,” and has proven to be excellent for animals (Mustafa et al. 1999).
In some areas where cannabis use had been historically tolerated, new restrictions were instituted, such as the closing of cannabis coffee shops near the borders of the Netherlands,[222] and closing of coffee shops near secondary schools in the Netherlands.[223] In Copenhagen, Denmark in 2014, mayor Frank Jensen discussed possibilities for the city to legalize cannabis production and commerce.[224]
Hemp, grown under license mostly in Canada, is the most publicized “new” crop in North America. Until very recently the prohibition against drug forms of the plant prevented consideration of cultivation of fiber and oilseed cultivars in Canada. However, in the last 10 years three key developments occurred: (1) much-publicized recent advances in the legal cultivation of hemp in western Europe, especially for new value-added products; (2) enterprising farmers and farm groups became convinced of the agricultural potential of hemp in Canada, and obtained permits to conduct experimental cultivation; and (3) lobby groups convinced the government of Canada that narcotic forms of the hemp plant are distinct and distinguishable from fiber and oilseed forms. In March 1998, new regulations (under the Controlled Drugs and Substances Act) were provided to allow the commercial development of a hemp industry in Canada, and since then more than a thousand licenses have been issued. Hectares licensed for cultivation for 1998–2001 were respectively, 2,500, 14,200, 5,487, and 1,355, the decreasing trend due to a glut of seed produced in 1999 and pessimism over new potential regulations barring exports to the US. Information on the commercial potential of hemp in Canada is in Blade (1998), Marcus (1998), and Pinfold Consulting (1998). In the US, a substantial trade in hemp products has developed, based on imports of hemp fiber, grain, and oil. The American agricultural community has observed this, and has had success at the state level in persuading legislators of the advisability of experimental hemp cultivation as a means of evaluating the wisdom of re-establishing American hemp production. However, because of opposition by the federal government, to date there has only been a small experimental plot in Hawaii. Information on the commercial potential of hemp in the US is presented in the following.

Thapa, D., Toguri, J. T., Szczesniak, A. M., & Kelly, A. E. M. (2017, April 1). The non-psychoactive phytocannabinoid, cannabidiol (CBD), and the synthetic derivatives, HU308 and CBD-DMH, reduces hyperalgesia and inflammation in a mouse model of corneal injury [Abstract]. FASEB Journal.  https://www.fasebj.org/doi/abs/10.1096/fasebj.31.1_supplement.811.7
Donna Gregory Burch was diagnosed with fibromyalgia in 2014 after several years of unexplained pain, fatigue and other symptoms. She was later diagnosed with chronic Lyme disease. Donna covers news, treatments, research and practical tips for living better with fibromyalgia and Lyme on her blog, FedUpwithFatigue.com. You can also find her on Facebook and Twitter. Donna is an award-winning journalist whose work has appeared online and in newspapers and magazines throughout Virginia, Delaware and Pennsylvania. She lives in Delaware with her husband and their many fur babies.
The clinical trials performed with Sativex have recently been assessed in two independent review articles (Barnes 2006; Pérez 2006). In a Phase II clinical trial in 20 patients with neurogenic symptoms (Wade et al 2003), Tetranabinex, Nabidiolex, and Sativex were tested in a double-blind RCT vs placebo (Table 1). Significant improvement was seen with both Tetranabinex and Sativex on pain (especially neuropathic), but post-hoc analysis showed symptom control was best with Sativex (p < 0.0001), with less intoxication than with THC-predominant extract.
Both in Canada and the US, the most critical problem to be addressed for commercial exploitation of C. sativa is the possible unauthorized drug use of the plant. Indeed, the reason hemp cultivation was made illegal in North America was concern that the hemp crop was a drug menace. The drug potential is, for practical purposes, measured by the presence of THC. THC is the world’s most popular illicit chemical, and indeed the fourth most popular recreational drug, after caffeine, alcohol, and nicotine. “Industrial hemp” is a phrase that has become common to designate hemp used for commercial non-intoxicant purposes. Small and Cronquist (1976) split C. sativa into two subspecies: C. sativa subsp. sativa, with less than 0.3% (dry weight) of THC in the upper (reproductive) part of the plant, and C. sativa subsp. indica (Lam.) E. Small & Cronq. with more than 0.3% THC. This classification has since been adopted in the European Community, Canada, and parts of Australia as a dividing line between cultivars that can be legally cultivated under license and forms that are considered to have too high a drug potential. For a period, 0.3% was also the allowable THC content limit for cultivation of hemp in the Soviet Union. In the US, Drug Enforcement Agency guidelines issued Dec. 7, 1999 expressly allowed products with a THC content of less than 0.3% to enter the US without a license; but subsequently permissible levels have been a source of continuing contention. Marijuana in the illicit market typically has a THC content of 5% to 10% (levels as high as 25% have been reported), and as a point of interest, a current Canadian government experimental medicinal marijuana production contract calls for the production of 6% marijuana. As noted above, a level of about 1% THC is considered the threshold for marijuana to have intoxicating potential, so the 0.3% level is conservative, and some countries (e.g. parts of Australia, Switzerland) have permitted the cultivation of cultivars with higher levels. It should be appreciated that there is considerable variation in THC content in different parts of the plant. THC content increases in the following order: achenes (excluding bracts), roots, large stems, smaller stems, older and larger leaves, younger and smaller leaves, flowers, perigonal bracts covering both the female flowers and fruits. It is well known in the illicit trade how to screen off the more potent fractions of the plant in order to increase THC levels in resultant drug products. Nevertheless, a level of 0.3% THC in the flowering parts of the plant is reflective of material that is too low in intoxicant potential to actually be used practically for illicit production of marijuana or other types of cannabis drugs. Below, the problem of permissible levels of THC in food products made from hempseed is discussed. 

To my understanding, neither CBD nor THC are effective for “severe” pain; rather, they work better for mild to moderate chronic pain. Often, with severe pain, the dosage of opiates can be decreased with concomitant use of medical cannabis or CBD and that decrease in dose makes their use safer. Concurrent use of THC does increase the analgesic effect of CBD, but it also adds the “high” which some people do not want as a side effect.

That’s our two cents worth. We are still reserching products with claims of effective pain relief and possibly something will work. As of right now if dot/gov can not point the now abandoned pain management patient to an effective pain management product, not willing to listen to our physicians or VERY negatively affected patients with a maximum, unilateral dosage of opioid medication new “policy”, then where do we turn for real, effective, pain management?